Published in Eur J Nucl Med Mol Imaging on February 09, 2010
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage (2013) 1.17
Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain (2011) 0.98
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Disclosure of amyloid imaging results to research participants: has the time come? Alzheimers Dement (2013) 0.91
Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. J Nucl Med (2013) 0.86
Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers. Eur J Nucl Med Mol Imaging (2012) 0.84
Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2016) 0.79
Classification of amyloid status using machine learning with histograms of oriented 3D gradients. Neuroimage Clin (2016) 0.78
Brain Amyloid Deposition and Longitudinal Cognitive Decline in Nondemented Older Subjects: Results from a Multi-Ethnic Population. PLoS One (2015) 0.76
Inter-rater variability of visual interpretation and comparison with quantitative evaluation of (11)C-PiB PET amyloid images of the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging (2016) 0.75
Agreement among neuropsychological and behavioral data and PiB findings in diagnosing Frontotemporal Dementia. J Clin Neurosci (2017) 0.75
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab (1996) 9.49
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry (1992) 4.16
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology (2006) 4.06
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology (2000) 2.73
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull (1988) 2.50
The dementias. Lancet (2002) 2.42
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol (1998) 1.86
Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology (2006) 1.85
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 1.39
PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain (2008) 1.34
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med (2009) 1.27
Simplified parametric methods for [11C]PIB studies. Neuroimage (2008) 1.23
Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging (2009) 0.87
Cognitive impairment in dementia: correlations with atrophy and cerebrovascular disease quantified by magnetic resonance imaging. Brain Cogn (2002) 0.76
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol (2010) 4.19
Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res (2009) 3.01
Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet (2004) 2.91
The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil (2005) 2.78
Delirium is a strong risk factor for dementia in the oldest-old: a population-based cohort study. Brain (2012) 2.64
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Association between blood pressure and survival over 9 years in a general population aged 85 and older. J Am Geriatr Soc (2006) 2.21
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Cardiac remodeling in a new pig model of chronic heart failure: Assessment of left ventricular functional, metabolic, and structural changes using PET, CT, and echocardiography. J Nucl Cardiol (2015) 2.10
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med (2008) 1.77
Self-reported sleep duration and cognitive functioning in the general population. J Sleep Res (2009) 1.71
Myocardial perfusion quantitation with 15O-labelled water PET: high reproducibility of the new cardiac analysis software (Carimas). Eur J Nucl Med Mol Imaging (2009) 1.71
Effects of sevoflurane, propofol, and adjunct nitrous oxide on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology (2003) 1.70
Education, the brain and dementia: neuroprotection or compensation? Brain (2010) 1.68
Clinical value of absolute quantification of myocardial perfusion with (15)O-water in coronary artery disease. Circ Cardiovasc Imaging (2011) 1.64
The effect of correcting for troponins on trends in coronary heart disease events in Finland during 1993-2002: the FINAMI study. Eur Heart J (2006) 1.63
Significant improvement in breast cancer survival through population-based mammography screening. Breast (2003) 1.63
Effects of surgical levels of propofol and sevoflurane anesthesia on cerebral blood flow in healthy subjects studied with positron emission tomography. Anesthesiology (2002) 1.62
The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. Eur J Cardiovasc Prev Rehabil (2007) 1.61
Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med (2010) 1.61
Binge drinking in midlife and dementia risk. Epidemiology (2005) 1.61
Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci (2005) 1.58
Effects of dementia on perceived daily pain in home-dwelling elderly people: a population-based study. Age Ageing (2004) 1.56
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
Approaches to quantify radioligands that wash out slowly from target organs. Eur J Nucl Med Mol Imaging (2010) 1.52
Increased incidence of hip fractures. A population based-study in Finland. Bone (2006) 1.50
Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study. Eur J Clin Pharmacol (2006) 1.49
Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf (2011) 1.47
Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse (2007) 1.46
Brain white matter expansion in human obesity and the recovering effect of dieting. J Clin Endocrinol Metab (2007) 1.46
Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging (2009) 1.45
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage (2009) 1.42
Absorption, distribution and excretion of intravenously injected (68)Ge/ (68)Ga generator eluate in healthy rats, and estimation of human radiation dosimetry. EJNMMI Res (2015) 1.38
Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes (2006) 1.37
Returning from oblivion: imaging the neural core of consciousness. J Neurosci (2012) 1.34
Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab (2007) 1.34
Dorsal striatum and its limbic connectivity mediate abnormal anticipatory reward processing in obesity. PLoS One (2012) 1.33
Does initial breastfeeding lead to lower blood cholesterol in adult life? A quantitative review of the evidence. Am J Clin Nutr (2008) 1.33
Is emotional contagion special? An fMRI study on neural systems for affective and cognitive empathy. Neuroimage (2008) 1.32
A new definition for myocardial infarction: what difference does it make? Eur Heart J (2005) 1.32
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Patterns of drug use and factors associated with polypharmacy and excessive polypharmacy in elderly persons: results of the Kuopio 75+ study: a cross-sectional analysis. Drugs Aging (2009) 1.31
Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med (2009) 1.31
Characteristics of two telephone screens for cognitive impairment. Dement Geriatr Cogn Disord (2002) 1.31
Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med (2008) 1.30
Effects of working-memory training on striatal dopamine release. Science (2011) 1.30
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem (2011) 1.29
Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain (2003) 1.29
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem (2013) 1.29
S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology (2005) 1.19
Intensive geriatric rehabilitation of hip fracture patients: a randomized, controlled trial. Acta Orthop Scand (2002) 1.19
Continuous 15-year decrease in incidence and mortality of stroke in Finland: the FINSTROKE study. Stroke (2004) 1.18
Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord (2008) 1.15
Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology (2003) 1.14
Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) (2005) 1.14
Diabetes worsens the outcome of acute ischemic stroke. Diabetes Res Clin Pract (2005) 1.12
High intensity exercise decreases global brain glucose uptake in humans. J Physiol (2005) 1.11
Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging (2014) 1.11
Altered dopamine D2 receptor binding in atypical facial pain. Pain (2003) 1.10
Increased brain fatty acid uptake in metabolic syndrome. Diabetes (2010) 1.10
C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse (2009) 1.10
B-type natriuretic peptide as a predictor of declining cognitive function and dementia--a cohort study of an elderly general population with a 5-year follow-up. Ann Med (2010) 1.09
Mesolimbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage (2012) 1.07
Planar scintigraphy with 123I/99mTc-sestamibi, 99mTc-sestamibi SPECT/CT, 11C-methionine PET/CT, or selective venous sampling before reoperation of primary hyperparathyroidism? J Nucl Med (2013) 1.07
Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. Neurobiol Aging (2012) 1.07
Combined hearing and visual impairment and depression in a population aged 75 years and older. Int J Geriatr Psychiatry (2002) 1.06
FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol (2012) 1.05
Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse (2015) 1.05
Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord (2006) 1.05
Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly finns: a population-based intervention study. Drugs Aging (2010) 1.05
Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy. J Nucl Med (2010) 1.04
Functional imaging studies of dopamine system and cognition in normal aging and Parkinson's disease. Neurosci Biobehav Rev (2002) 1.04
Concomitant use of analgesics and psychotropics in home-dwelling elderly people-Kuopio 75 + study. Br J Clin Pharmacol (2005) 1.04
The non-use of hearing aids in people aged 75 years and over in the city of Kuopio in Finland. Eur Arch Otorhinolaryngol (2004) 1.03
Mobile phone affects cerebral blood flow in humans. J Cereb Blood Flow Metab (2006) 1.03
Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord (2004) 1.03
Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes (2005) 1.02
Socioeconomic inequalities in the morbidity and mortality of acute coronary events in Finland: 1988 to 2002. Ann Epidemiol (2012) 1.02
Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab (2008) 1.02